<DOC>
	<DOCNO>NCT00000881</DOCNO>
	<brief_summary>Part A : To determine safety pharmacokinetics sequential single dos cidofovir HIV-infected child end-organ cytomegalovirus ( CMV ) disease . Part B : To determine safety ( include time progression CMV retinitis retinal exam ) , pharmacokinetics , long-term ( 6 month ) tolerance multiple-dose cidofovir HIV-infected child CMV retinitis . Part B : To determine effect multiple-dose cidofovir virologic parameter CMV retinitis ( viral load , shed , resistance antiviral agent ) . [ AS PER AMENDMENT 1/7/98 : To determine safety , tolerance pharmacokinetics sequential single dos cidofovir HIV-infected child CMV retinitis . To determine safety ( include time progression CMV retinitis retinal exam ) , pharmacokinetics , long-term ( 6-month ) tolerance multiple dos cidofovir HIV-infected child CMV retinitis . ] While intravenous formulation cidofovir approve treatment CMV retinitis HIV-infected individual , information limit regard safety tolerance HIV-infected child . Intravenous cidofovir require less frequent administration induction maintenance therapy CMV retinitis currently available therapy . If find safe well tolerate HIV-infected child CMV retinitis , intravenous cidofovir would add significantly agent available treat debilitate opportunistic infection .</brief_summary>
	<brief_title>A Study Cidofovir HIV-Infected Children With Cytomegalovirus ( CMV ) Disease</brief_title>
	<detailed_description>While intravenous formulation cidofovir approve treatment CMV retinitis HIV-infected individual , information limit regard safety tolerance HIV-infected child . Intravenous cidofovir require less frequent administration induction maintenance therapy CMV retinitis currently available therapy . If find safe well tolerate HIV-infected child CMV retinitis , intravenous cidofovir would add significantly agent available treat debilitate opportunistic infection . In two-part study , patient stratify age ( 3 month &lt; 2 year versus 2 year &lt; 13 year ) . In Part A , 8 patient ( 4 per cohort ) receive single intravenous dose cidofovir concurrent probenecid . If 1 patient cohort experience life-threatening grade 3/4 toxicity , accrual cohort stop . If 1 patient cohort experience non-life-threatening grade 3/4 toxicity , 2 additional patient enter cohort . A second dose cidofovir may study Part A base pharmacokinetic safety data obtain initial dose . Patients complete Part A study without serious toxicity may treat Part B . In Part B , 12 patient ( 8 old cohort 4 young cohort ) receive maintenance therapy cidofovir dose establish Part A . Patients complete 6 month treatment Part B may continue therapy patient complete study . NOTE : For patient require induction reinduction , cidofovir give weekly 2 week initiate Part B regimen . [ AS PER AMENDMENT 1/7/98 : Each subject receive sequential single dos intravenous cidofovir , 2-week interval dos concurrent probenecid . If single dos prove safe well tolerate individual pharmacokinetic profile acceptable , subject proceed multi-dosing cidofovir give every 2 week 6 month begin 14-21 day second single dose . Subjects remain intravenous oral ganciclovir treatment CMV retinitis enter multi-dosing phase study . Subjects require reinduction multi-dosing phase receive intravenous cidofovir weekly 2 week resume every-2-weeks regimen . Patients stratified age ( 3 month &lt; 2 year vs. 2 year &lt; 13 year ) , 4 patient enter young cohort 8 older . In young age cohort , 1 patient experience life- vision-threatening grade 3/4 toxicity 2 experience non-life-threatening grade 3/4 toxicity , age cohort stop . If 1 patient experience non-life-threatening grade 3/4 toxicity , 2 additional patient enrol age cohort . In old age cohort , 1 patient experience severe life- vision-threatening toxicity 2 experience serious , non-life-threatening toxicity , enrollment cohort suspend safety data review . If 2 8 patient experience severe , non-life-threatening toxicity , enrollment may continue . ]</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Ganciclovir therapy ( patient Part A ) . [ AS PER AMENDMENT 1/7/98 : Ganciclovir require sequential singledose phase . ] Antiretroviral medication , include protease inhibitor . Antibacterials except aminoglycosides . IVIG . Antihistamines , antiemetic , acetaminophen . Patients must : Documented laboratory evidence HIV1 infection demonstrate : &lt; 18 month age : positive viral culture second confirmatory test ( later date ) either positive viral culture , p24 antigen , PCR . Confirmatory test must complete ACTG certify laboratory . &gt; = 18 month age : criterion state &lt; 18 month 2 positive test HIV antibody obtain 18 month age ( draw two different date ) . HIV antibody test must determine federally license ELISA . One two positive HIV antibody test must confirm confirmatory test ( Western blot IFA ) . Part A : Endorgan CMV disease document histopathologic diagnosis compatible clinical disease positive CMV culture and/or CMV PCR need administer antiCMV agent determine patient 's physician . Part B : CMV retinitis document retinal exam require antiCMV agent determine patient 's physician . Patients CMV retinitis successfully complete Part A without significant toxicity eligible participate Part B . Signed , inform consent parent legal guardian patient &lt; 18 year age . [ AS PER AMENDMENT 1/7/98 : Documented active inactive CMV retinitis ( retinal examination ) need administer antiCMV agent determine subject 's physician . Subjects may receive either induction maintenance ganciclovir entry ( therapy must complete prior proceed multidosing phase ) . ] Prior Medication : Required : Ganciclovir therapy upon entry ( patient Part A ) . Allowed : Ganciclovir therapy upon entry ( patient Part B ) . NOTE : Patients Part B allow receive concomitant CMV therapy study drug start . [ AS PER AMENDMENT 1/7/98 : Patients require receive ganciclovir sequential singledose phase must receive concurrent CMV therapy multidosing phase initiate . ] Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Acute infection require treatment study period . Concurrent Medication : Excluded : Cancer chemotherapeutic agent . [ AS PER AMENDMENT 1/7/98 : Anticancer therapy prohibit multidosing phase . ] Excluded within 7 day prior enrollment : Foscarnet therapy . Drugs know cause nephrotoxicity amphotericin B , aminoglycosides , vancomycin , IV pentamidine . Other local systemic antiCMV medication ( except concomitant ganciclovir patient treat Part A ) . Patients follow prior condition exclude : Previous hypersensitivity reaction probenecid and/or serious allergic reaction ( e.g. , anaphylactic reaction , hypotension , laryngospasm , exfoliative dermatitis ) sulfacontaining medication . [ AS PER AMENDMENT 1/7/98 : Preexisting uveitis/iritis determine slitlamp exam . Intraocular pressure &lt; 4 mm Hg prior enrollment . ]</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>cidofovir</keyword>
</DOC>